Mathematical optimisation of the cisplatin plus etoposide combination for managing extensive-stage small-cell lung cancer patients

BACKGROUND: Small-cell lung cancer (SCLC) represents one of the most aggressive forms of lung cancer. Despite the fair sensitivity of SCLC to chemotherapy and radiotherapy, the current standard treatment regimens have modest survival rates and are associated with potential life-threatening adverse e...

Descripción completa

Detalles Bibliográficos
Autores principales: Faivre, C, El Cheikh, R, Barbolosi, D, Barlesi, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294490/
https://www.ncbi.nlm.nih.gov/pubmed/28081545
http://dx.doi.org/10.1038/bjc.2016.439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5294490/
https://www.ncbi.nlm.nih.gov/pubmed/28081545
http://dx.doi.org/10.1038/bjc.2016.439

Ejemplares similares